Tumor lysis syndrome

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Constipation, Leukopenia, Risk, Woman, Tremor, Nausea, Cancer, Infection, Back pain, Anatomy, Cough, IIA, Chills, Diarrhea, Fever, ATC, Insomnia, Bone marrow, Pain, Disease, Philadelphia chromosome, Edema, Neutrophil, Human, Safety, ALL, Water, Anemia, Tumor lysis syndrome, Leukemia, Blood pressure, Patient, Medical Subject Headings, Febrile neutropenia, Agency, MRD, Antibody, Cytokine release syndrome, International, Neutropenia, Blood, Language, Dizziness, Thrombocytopenia, Nervous system, Select, Vomiting, CD3, Acute leukemia, Headache, Swelling, Hypoesthesia, Confusion, European Medicines Agency, Cell, CD19, Paresthesia, Rash, Medical device

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Risk, Constipation, Needle, Body surface area, Nausea, DNA, Cancer, T-ALL, Anatomy, Paresthesia, Cough, IIA, Hypoesthesia, Diarrhea, Fever, Fatigue, Infection, Bone marrow, ATC, Pain, Disease, Ageing, Somnolence, Periodic breathing, Cerebral edema, Edema, Enzyme, Safety, Anemia, Tumor lysis syndrome, Patient, Medical Subject Headings, Febrile neutropenia, Agency, Guanine, International, Paralysis, LBL, Neutropenia, Blood, Language, Myalgia, Dizziness, Thrombocytopenia, Nervous system, Thymus, Select, Vomiting, Peripheral neuropathy, Survival, Lymph, Extremities, System, Weakness, Headache, Brain, Swelling, European Medicines Agency, Convulsion, Growth, Cell, Lymphatic system, Medical device

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Febuxostat Krka, febuxostat, Date of authorisation: 28/03/2019, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, INN, Risk, ATC, Joint, Pain, International, Uric acid, Xanthine oxidase, Blood, Language, Inflammation, Cancer, History, European Medicines Agency, Tablet, Select, Patient, Anatomy, Bone marrow, IIA, Tumor lysis syndrome, Tophus, Medical device

Human medicines European public assessment report (EPAR): Febuxostat Krka, febuxostat, Date of authorisation: 28/03/2019, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Febuxostat Krka, febuxostat, Date of authorisation: 28/03/2019, Revision: 5, Status: Authorised

BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Dexamethasone, Multiple myeloma, BCL2, Safety, PST, Tumor lysis syndrome, BGNE, BTK, Lymphoid leukemia, Bone marrow, Harbor Drive, ASH, US Foods, Patient, Abstract, PFS, TLS, Enterprise Community Partners, Q&A, Acalabrutinib, SSE, Blood, Exposition, CDAC, Cancer, Mental health, Recurrence, Orphan, Society, HIV disease progression rates, Pharmaceutical industry, Vaccine, BeiGene, Hematology

BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.

Key Points: 
  • BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.
  • “Our data at ASH showcase BeiGene’s leadership in the treatment of blood cancers, with promising clinical advances across our pipeline.
  • BeiGene will host an event in San Diego on Sunday, December 10 at 8:00 pm PST for investors and analysts attending ASH.
  • BeiGene senior management and invited speakers will review BeiGene’s pipeline and highlights of the presented data, followed by a Q&A panel.

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

Retrieved on: 
Thursday, June 29, 2023
CLL, Hypersensitivity, Lymphocytosis, Pimozide, Arrhythmia, Tacrolimus, Chronic lymphocytic leukemia, SLL, Liver disease, Simvastatin, Magnesium, Atorvastatin, Antifungal, Person, QT, Sirolimus, QT interval, Ergot, Alkaline phosphatase, Plasma, Kidney, Lovastatin, Ergotism, Patient, Azole, Risk, Electrolyte, Ergotamine, Dihydroergotamine, Tumor lysis syndrome, Ciclosporin, ALT, Quinidine, Rhabdomyolysis, Potassium, AST, Venetoclax, Pharmaceutical industry, Posaconazole, CYP3A4

Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.

Key Points: 
  • Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.
  • Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism.
  • Reserve azole antifungals, including posaconazole injection, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
  • Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older.

Endo Launches First Generic Version of Noxafil® (posaconazole) Injection

Retrieved on: 
Thursday, June 29, 2023
CLL, Hypersensitivity, Lymphocytosis, Pimozide, Arrhythmia, Tacrolimus, Chronic lymphocytic leukemia, SLL, Liver disease, Simvastatin, Magnesium, Atorvastatin, Antifungal, Person, QT, Sirolimus, QT interval, Ergot, Alkaline phosphatase, Plasma, Kidney, Lovastatin, Ergotism, Patient, Azole, Risk, Electrolyte, Ergotamine, Dihydroergotamine, Tumor lysis syndrome, Ciclosporin, ALT, Quinidine, Rhabdomyolysis, Potassium, AST, Venetoclax, Pharmaceutical industry, Posaconazole, CYP3A4

Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.

Key Points: 
  • Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity.
  • Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism.
  • Reserve azole antifungals, including posaconazole injection, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
  • Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older.

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

Retrieved on: 
Tuesday, June 6, 2023
Armed Forces Radiobiology Research Institute, Neutropenia, PK, Rituximab, Mayo Clinic, CXCR4, Diarrhea, Arm, TLS, Aes, DLT, Cancer, DDI, Pharmacokinetics, Mutation, CHB, MTTR, Appetite, Abdominal pain, WM, ASCO, Kidney, American Society of Clinical Oncology, Patient, Risk, Anemia, Apoptosis, Annual general meeting, Tumor lysis syndrome, Nausea, MTD, Bone marrow, Poster, Principal, Leukopenia, Notifiable disease, Society, Thrombocytopenia, ORR, Hepatitis, Safety, Common, Pharmaceutical industry, MD

"In this global Phase Ib/II study, lisaftoclax monotherapy showed encouraging antitumor activity and satisfactory safety profile in patients with relapsed/refractory (R/R) WM who had received prior treatment with BTKis.

Key Points: 
  • "In this global Phase Ib/II study, lisaftoclax monotherapy showed encouraging antitumor activity and satisfactory safety profile in patients with relapsed/refractory (R/R) WM who had received prior treatment with BTKis.
  • This drug's other attributes include the patient friendly daily dose ramp-up schedule which allows for faster attainment of target therapeutic doses.
  • "In particular, the lisaftoclax plus BTKi regimen has demonstrated an impressive ORR that signalled exciting clinical potential.
  • Appendix: The four posters on Ascentage Pharma's four lead drug candidates, including lisaftoclax, presented at this year's ASCO Annual Meeting.

Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022

Retrieved on: 
Sunday, December 11, 2022
Research, Hospitals, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Liver, Phase, Pain scale, Society, Rituximab, NHL, B-cell lymphoma, Lymphoma, Patient, ROG, Pharmacokinetics, Risk, DLBCL, Rash, Skin, Prednisone, Doxorubicin, RO, ADC, Death, Fatigue, Muscle weakness, Pain, Abdomen, Vincristine, Quality of life (healthcare), Tumor lysis syndrome, Infection, Dizziness, Confusion, Food, CD79B, Chills, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cough, Oxaliplatin, Diarrhea, PFS, Overalls, Urination, ASH, Exposition, Arm, Salvage therapy, Nausea, Progression-free survival, Vomiting, Weight loss, Survival, Safety, Hoffmann-La Roche, Walking, Fever, Cyclophosphamide, Fine chemical, Pharmaceutical industry, Medical device, Vaccine, Genentech, Polatuzumab vedotin, EU

Data from the POLARIX study support the potential benefit of Polivy in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to improve outcomes for people with previously untreated diffuse large B-cell lymphoma (DLBCL).

Key Points: 
  • Data from the POLARIX study support the potential benefit of Polivy in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to improve outcomes for people with previously untreated diffuse large B-cell lymphoma (DLBCL).
  • Too many patients with diffuse large B-cell lymphoma see their cancer relapse or progress after initial treatment.
  • These updated POLARIX data indicate the potential benefits that this Polivy based-regimen could bring to people living with this aggressive type of lymphoma, and demonstrate our commitment to developing new treatment options.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkins lymphoma (NHL), accounting for about one in three cases of NHL.

Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Retrieved on: 
Thursday, December 8, 2022
Health, Science, Pharmaceutical, Research, Oncology, Thrombocytopenia, Pralatrexate, Dialysis, Kidney, Fresenius (company), Patient, Toxicity, Liver function tests, Probenecid, Nausea, Mucositis, Fatigue, FDA, Risk, Birth, Multimedia, Tumor lysis syndrome, Fetus, ANC, Platelet, Pharmaceutical industry, Medical imaging, Birth control, Health, Science, Pharmaceutical, Research, Oncology

Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn, for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Key Points: 
  • Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn, for the treatment of relapsed or refractory peripheral T-cell lymphoma.
  • (Photo: Business Wire)
    Fresenius Kabi is committed to expanding access to high-quality, high-value oncology medicines, said John Ducker, president and CEO of Fresenius Kabi USA.
  • Fresenius Kabi Pralatrexate Injection provides clinicians and patients with a generic treatment option for adult patients with relapsed or refractory peripheral T-cell lymphoma.
  • Fresenius Kabi Pralatrexate Injection is available in two single-dose vial presentations: 20 mg/1 mL and 40 mg/2 mL.

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Retrieved on: 
Wednesday, December 7, 2022
CLL, Heart, Food, Rash, Teva, Cough, NHL, Patient, Diarrhea, Chronic lymphocytic leukemia, Research, Food and Drug Administration, Nausea, Aplastic anemia, Headache, United States National Library of Medicine, Fatigue, FDA, Vomiting, Injection, Breathe Me, US Foods, MedlinePlus, Pharmacist, Anaphylaxis, Growth, Constipation, AP, Safety, Purging disorder, Accord, National library, Infection, Tumor lysis syndrome, Rituximab, Intas Biopharmaceuticals, MEDLINE, Pharmaceutical industry, Fever, Bendamustine

DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Bendamustine Lyo. Injection to its line of chemotherapy drugs. Accord's product is AP rated to Teva's Treanda® and is being offered in both 25-mg and 100-mg vials.

Key Points: 
  • DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Bendamustine Lyo.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.
  • Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do.